Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAPNASDAQ:GNTANASDAQ:VYNENASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.28+5.0%$0.28$0.20▼$1.48$71.49M2.861.83 million shs415,897 shsGNTAGenenta Science$4.25+1.0%$3.94$2.79▼$7.28$77.00M0.6614,734 shs1,541 shsVYNEVYNE Therapeutics$1.22-2.4%$1.59$1.18▼$4.30$18.56M1.76100,572 shs101,150 shsXCURExicure$10.06-2.3%$11.73$1.44▼$36.00$63.56M3.86574,703 shs7,532 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics0.00%-5.02%+16.67%-51.92%-77.59%GNTAGenenta Science0.00%-2.07%+9.54%-2.75%+32.81%VYNEVYNE Therapeutics0.00%-6.15%-34.05%-50.61%-56.43%XCURExicure0.00%-12.06%+19.19%+0.30%+1,861.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAPAdaptimmune Therapeutics2.7888 of 5 stars4.24.00.00.02.30.80.0GNTAGenenta Science1.5513 of 5 stars3.53.00.00.00.01.70.0VYNEVYNE Therapeutics2.0092 of 5 stars3.53.00.00.00.61.70.6XCURExicure1.5065 of 5 stars0.05.00.04.70.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 2.43Hold$1.52446.36% UpsideGNTAGenenta Science 3.00Buy$25.00488.24% UpsideVYNEVYNE Therapeutics 3.00Buy$6.25412.30% UpsideXCURExicure 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VYNE, ADAP, GNTA, and XCUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.005/14/2025ADAPAdaptimmune TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.464/25/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.75 ➝ $4.504/11/2025ADAPAdaptimmune TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/1/2025ADAPAdaptimmune TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.003/26/2025ADAPAdaptimmune TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.753/21/2025ADAPAdaptimmune TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $1.503/21/2025ADAPAdaptimmune TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$3.15 ➝ $1.403/6/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.75 ➝ $5.752/19/2025VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.75 ➝ $5.75(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$178.03M0.40N/AN/A$0.17 per share1.63GNTAGenenta ScienceN/AN/AN/AN/A$1.21 per shareN/AVYNEVYNE Therapeutics$605K30.67N/AN/A$6.36 per share0.19XCURExicure$500K127.12N/AN/A$1.75 per share5.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$113.87M-$0.27N/AN/AN/A-25.43%-74.15%-15.09%N/AGNTAGenenta Science-$12.60MN/A0.00N/AN/AN/AN/AN/AN/AVYNEVYNE Therapeutics-$28.45M-$0.99N/AN/AN/A-6,896.55%-43.73%-38.55%N/AXCURExicure-$16.91M-$4.81N/A∞N/AN/A-190.90%-36.75%6/4/2025 (Estimated)Latest VYNE, ADAP, GNTA, and XCUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ADAPAdaptimmune Therapeutics-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million5/8/2025Q1 2025VYNEVYNE Therapeutics-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 million3/24/2025Q4 2024ADAPAdaptimmune Therapeutics-$0.17-$0.26-$0.09-$0.29$16.56 million$3.22 million3/18/2025Q4 2024XCURExicureN/A-$3.39N/A-$3.39N/AN/A3/6/2025Q4 2024VYNEVYNE Therapeutics-$0.31-$0.28+$0.03-$0.28$0.14 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune Therapeutics0.623.853.82GNTAGenenta ScienceN/A9.31N/AVYNEVYNE TherapeuticsN/A5.815.81XCURExicureN/A0.710.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%GNTAGenenta Science15.13%VYNEVYNE Therapeutics83.78%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.74%GNTAGenenta Science28.99%VYNEVYNE Therapeutics4.80%XCURExicure3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490257.23 million224.05 millionOptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableVYNEVYNE Therapeutics3015.21 million14.04 millionNot OptionableXCURExicure506.32 million2.50 millionNot OptionableVYNE, ADAP, GNTA, and XCUR HeadlinesRecent News About These CompaniesExicure, Inc. (NASDAQ:XCUR) Short Interest Down 19.8% in AprilMay 4, 2025 | marketbeat.comWhy Exicure Inc. (XCUR) Soared on MondayApril 22, 2025 | msn.comExicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short InterestApril 20, 2025 | marketbeat.comExicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myelomaApril 16, 2025 | pharmabiz.comExicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100April 15, 2025 | pharmabiz.comExicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple MyelomaApril 14, 2025 | businesswire.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...April 11, 2025 | gurufocus.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | investing.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | businesswire.comWednesday’s Insider Moves: Top Buys and Sells in US StocksMarch 27, 2025 | investing.comExicure, Inc. Reports Full Year 2024 Financial ResultsMarch 18, 2025 | gurufocus.comExicure secures Australian patent for cancer treatmentMarch 15, 2025 | investing.comExicure announces issuance of new patent in AustraliaMarch 15, 2025 | markets.businessinsider.comExicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in AustraliaMarch 13, 2025 | gurufocus.comKuehn Law Encourages Investors of Exicure, Inc. to Contact Law FirmJanuary 27, 2025 | markets.businessinsider.comExicure announces purchase agreement with GPCR TherapeuticsJanuary 24, 2025 | markets.businessinsider.comCORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.January 23, 2025 | businesswire.comExicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.January 22, 2025 | businesswire.comWhen the Price of (XCUR) Talks, People ListenJanuary 21, 2025 | news.stocktradersdaily.comWhen (XCUR) Moves Investors should ListenJanuary 11, 2025 | news.stocktradersdaily.com(XCUR) Technical Pivots with Risk ControlsJanuary 1, 2025 | news.stocktradersdaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVYNE, ADAP, GNTA, and XCUR Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.28 +0.01 (+4.99%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.28 0.00 (-0.32%) As of 05/16/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Genenta Science NASDAQ:GNTA$4.28 +0.07 (+1.57%) As of 05/16/2025 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.VYNE Therapeutics NASDAQ:VYNE$1.22 -0.03 (-2.40%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.22 0.00 (-0.41%) As of 05/16/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.Exicure NASDAQ:XCUR$10.06 -0.24 (-2.33%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$10.04 -0.02 (-0.20%) As of 05/16/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
